Format
Sort by
Items per page

Send to

Choose Destination

Best matches for HYDROXYPROGESTERONE/PD:

Search results

Items: 1 to 20 of 5618

1.
2.

Oral and intrauterine progestogens for atypical endometrial hyperplasia.

Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N.

Cochrane Database Syst Rev. 2018 Dec 4;12:CD009458. doi: 10.1002/14651858.CD009458.pub3.

PMID:
30521671
3.
4.

Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.

Cover J, Namagembe A, Tumusiime J, Lim J, Cox CM.

Reprod Health. 2018 Oct 3;15(1):165. doi: 10.1186/s12978-018-0611-7.

5.

Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.

Kagan R, Abreu P, Andrews E.

Postgrad Med. 2018 Nov;130(8):687-693. doi: 10.1080/00325481.2018.1520046. Epub 2018 Oct 3.

PMID:
30280946
6.

Efficacy of progesterone for prevention of preterm birth.

Sykes L, Bennett PR.

Best Pract Res Clin Obstet Gynaecol. 2018 Oct;52:126-136. doi: 10.1016/j.bpobgyn.2018.08.006. Epub 2018 Sep 8. Review.

PMID:
30266582
7.

Changes to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response.

Nene Z, Hofmeyr GJ, Patel M, Panday M, Rees H, Makua M, Pillay Y.

S Afr Med J. 2018 Jul 25;108(8):629-631. doi: 10.7196/SAMJ.2018.v108i8.13160.

9.

Differential expressions of estrogen and progesterone receptors in endometria and cyst walls of ovarian endometrioma from women with endometriosis and their responses to depo-medroxyprogesterone acetate treatment.

Sroyraya M, Songkoomkrong S, Changklungmoa N, Poljaroen J, Weerakiet S, Sophonsritsuk A, Wongkularb A, Lertvikool S, Tingthanatikul Y, Sobhon P.

Mol Cell Probes. 2018 Aug;40:27-36. doi: 10.1016/j.mcp.2018.07.001. Epub 2018 Jul 3.

PMID:
30078406
10.

Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.

Cross-Barnet C, Courtot B, Benatar S, Hill I, Johnston E, Cheeks M.

Matern Child Health J. 2018 Nov;22(11):1607-1616. doi: 10.1007/s10995-018-2556-4. Erratum in: Matern Child Health J. 2018 Nov 30;:.

PMID:
29956128
11.

Efficacy Of 17- Α-Hydroxy-Progestrone In Prevention Of Preterm Labour In High Risk Pregnant Women.

Shadab W, Riaz S, Aftab F, Shah FH.

J Ayub Med Coll Abbottabad. 2018 Apr-Jun;30(2):209-212.

12.

Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda.

Cover J, Lim J, Namagembe A, Tumusiime J, Drake JK, Cox CM.

Int Perspect Sex Reprod Health. 2017 Dec 1;43(4):153-162. doi: 10.1363/43e5117.

PMID:
29771679
13.

Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.

Zeng Z, Jiang X, Li X, Wells A, Luo Y, Neapolitan R.

PLoS One. 2018 May 16;13(5):e0197064. doi: 10.1371/journal.pone.0197064. eCollection 2018.

14.

Rationale for current and future progestin-based therapies to prevent preterm birth.

Weatherborn M, Mesiano S.

Best Pract Res Clin Obstet Gynaecol. 2018 Oct;52:114-125. doi: 10.1016/j.bpobgyn.2018.03.008. Epub 2018 Apr 11. Review.

PMID:
29724668
15.

Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.

Maritz MF, Ray RM, Bick AJ, Tomasicchio M, Woodland JG, Govender Y, Avenant C, Hapgood JP.

PLoS One. 2018 Apr 26;13(4):e0196043. doi: 10.1371/journal.pone.0196043. eCollection 2018.

16.

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review.

Silva P, Qadir S, Fernandes A, Bahamondes L, Peipert JF.

Braz J Med Biol Res. 2018;51(6):e7575. doi: 10.1590/1414-431x20187575. Epub 2018 Apr 23. Review.

17.

Subclinical cardiovascular disease parameters after one year in new users of depot medroxyprogesterone acetate compared to copper-IUD.

Cursino K, de Lima GA, de Nazaré Silva Dos Santos P, Pavin EJ, Bahamondes L, Fernandes A.

Eur J Contracept Reprod Health Care. 2018 Jun;23(3):201-206. doi: 10.1080/13625187.2018.1455087. Epub 2018 Apr 19.

PMID:
29671344
18.

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC).

Stout A, Wood S, Namagembe A, Kaboré A, Siddo D, Ndione I.

Eval Program Plann. 2018 Jun;68:185-193. doi: 10.1016/j.evalprogplan.2018.03.004. Epub 2018 Mar 5.

19.

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.

Stout A, Wood S, Barigye G, Kaboré A, Siddo D, Ndione I.

Glob Health Sci Pract. 2018 Mar 30;6(1):55-72. doi: 10.9745/GHSP-D-17-00250. Print 2018 Mar 21.

20.

A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.

Shambhavi S, Bagga R, Bansal P, Kalra J, Kumar P.

J Obstet Gynaecol. 2018 Aug;38(6):800-806. doi: 10.1080/01443615.2018.1425380. Epub 2018 Mar 20.

PMID:
29557230

Supplemental Content

Loading ...
Support Center